The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
A positive press release about diagnostics today: Roche’s diagnostic business sales offer a bright spot in Q4
Elsewhere the company's pharmaceutical division slipped due to biosimilar competition. http://www.pmlive.com/pharma_news/roches_diagnostic_business_sales_offer_a_bright_spot_in_q4_1362786?SQ_DESIGN_NAME=2&utm_source=pmlive&utm_medium=email&utm_campaign=pmlive_daily&
Brentw - Well said. I wish people listen to what you have just said. The DHSC are tricky enough to deal with and don’t take well to badgering by shareholders like us.
Surely we can concentrate on sales successes overseas which normally don’t come with a No. Disclosure Agreement.
ShaunP
This therefore means that Overseas revenues were very good, in particular Germany, whom I feel we made have sold more into than any country, including the United Kingdom.
—————————————————————
If you are correct about this, then why on earth is the company not making more publicity about their overseas successes? I wish there was less obsession about the DHSC here because we all know getting permission from them to say anything about business is extremely difficult.
The White House announced Monday 1 February it is buying 8.5 million rapid coronavirus tests that can be taken at home without a prescription and that yield immediate results.
The $231.8 million contract will allow the Australian company Ellume, which manufacturers the tests, to quickly scale up its production and create a manufacturing facility in the United States. Once running, that factory will be able to produce 19 million tests per month.
https://www.washingtonpost.com/health/2021/02/01/coronavirus-home-test-ellume/
tkr234
RE: Reason for sell off today
O.K Nova cannot discuss Govt contracts/tenders,so does this also cover global as well,a few RNS,s of sales abroad would be a plus to the sp.IMHO
I agree totally tkr234
Everything is too parochial here and focused on the DHSC who must be a nightmare to do business with. Why don’t we talk about business outside the UK? If you want to be considered a market leader in diagnostics & innovation then what the UK does or doesn’t do is not likely to impress the French shareholders or anyone outside Europe either.
.../2
USA:
FDA approval exists for several of the Novacyt products and a network of distribution has been built up in the USA as well as Canada. The PR needs to highlight these facts and allow the company to receive credit for its expertise and innovation as well as its efforts in helping to win the battle against the COVID virus.
WORLDWIDE / ASIA/ AUSTRALIA/ S. AMERICA:
A similar network of distribution and sales successes already exists in many of these countries and the PR campaign needs to make more ‘noise’ about them. The additional fact of WHO approval will help to distance Novacyt above the widely perceived negative impression of the UK at combating Covid in these countries.
Candidates must be able to converse in French as well as English as all company PR must be available simultaneously in both languages.
Novacyt PR
Suggested Public Relations Brief for Novacyt in 2021:
Following the Novact Trading Results for 2020 which were greeted by the markets with an immediate drop in share price of almost 20%, the company is seeking to appoint a PR company to meet the following brief:
Critical Issues that need to be addressed in your submission:
A/ MANAGEMENT EXPERTISE: The company has increased its revenue, profits and staff count dramatically in the last 12 months and now needs help in explaining to outside influencers what has been achieved and where the management intend to position Novacyt in the future. In particular what are the prospects for further growth in 2021 - 2025 when COVID-19 may well be brought under control.
There is much to be proud of in achievements of this young fast-growing company but the management lacks the time and experience to identify what can be disclosed without affecting commercial security and what nuggets of information to expound for the greatest financial benefit.
DUAL FRANCE / UK LISTING:
For historical reasons Novacyt is dual listed on the French Bourse and on the AIM market in the UK under different codes ‘ALNOV’ and ‘NCYT’. Despite over 65% of the company’s shares being traded in the Paris market the company is even less known in France than in the UK.
The CEO is English and much of the recent innovation, product development seems to be led by the UK in Camberley and sales achievements in France appear to be rather disappointing when compared to the UK. The PR proposals need to address this situation to ensure staff in France at Vélizy and elsewhere do not feel they are ‘out of the loop’ and are kept equally informed of management decisions and opportunities to progress their careers.
At the same time the PR program needs to urgently raise awareness of Novacyt as a growing and highly innovative company in France as well as the UK. There needs to be indications of a long-term plan to become a world-leading diagnostics company with a bright future even after the Covid pandemic has been overcome.
EUROPEAN SUCCESS;
Novacyt already has substantial business success in other EU countries (Germany and Italy for example) and greater awareness of these sales successes would surely help to develop further business. The company needs to be more widely known as a successful European company in these markets.
USA:
FDA approval exists for several of the Novacyt products and a network of distribution has been built up in the USA as well as Canada. The PR needs to highlight these facts and allow the company to receive credit for its expertise and innovation as well as its efforts in helping to win the battle against the COVID virus.
WORLDWIDE / ASIA/ AUSTRALIA/ S. AMERICA:
A similar network of distribution and sales successes already exists in many of these countries and the PR campaign needs to make more ‘noise’ about them. The additional fact of WHO approval will help to distance Novacyt above the widely pe
I just saw this article about a symptomatic testing sites being opened up in Kent:
More symptom-free Covid-19 testing sites opening in Kent at Sandwich, Cranbrook, Ashford, Gravesend and Herne:
https://www.kentonline.co.uk/gravesend/news/more-symptom-free-test-sites-to-open-240930/
Hello Porky,
I was a bit concerned myself wondering where ShaunP was - particularly after he was ****ged off yesterday by one of the regulars who invited him to respond in kind.
However I was reassured later when I saw he told he is busy trialling his version of the end of year accounts which is very time consuming.
Also there is little worth saying now until the official figures are announced.
Tay, there must be a solution to this if we mull it over. I am greatly in favour of supporting a serious but open minded site with a joining or membership fee if you, Shaun a some of the other serous commentators were involved. Just find a way to delete the people who want to clog the board up with irrelevant gossip and moans!
Hi Shaun,
Tui Travel have a place on their website giving requirements by country of destination- see here https://www.tui.co.uk/destinations/info/entry-requirements
Thanks for that useful summary. I just sent it to my sister who has booked a test in Brighton (results promised in 15 minutes!) prior to meeting her daughter in law and granddaughter on Christmas Day.
Articles with headlines like this from yesterday’s D.Telegraph show what some journalists (badly informed) think: Stop wasting billions on testing. Only the vaccine can save us now
http://digitaleditions.telegraph.co.uk/data/450/reader/reader.html?social#!preferred/0/package/450/pub/450/page/77/article/113813
We know there are companies researching easier methods of taking swabs that are less intrusive etc that we must keep tabs on.